Andrew Baum

Type: Person

Name: Andrew Baum

First reported May 23 2013 - Updated May 23 2013 - 2 reports

Cancer drugs to rake in R340bn

A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35-billion a year.That bullish sales forecast by analysts at US bank Citigroup highlights the growing ... [Published iafrica.com - May 23 2013]

Entities: Cancer, Drugs, Immunotherapy, Immune System

First reported May 22 2013 - Updated May 22 2013 - 2 reports

Saks Incorporated

UPDATE 4: Wednesday's movers: Saks rallies for third day

SAN FRANCISCO (MarketWatch) -- Saks Inc. rallied for a third day Wednesday on reports that it may be window shopping for a new owner, with most analysts generally upbeat about a potential deal.GainersBristol-Myers Squibb Co. (BMY) shares rose 5.8% after ... [Published TD Ameritrade - May 22 2013]

Entities: Saks Incorporated, Stocks, Target Corporation, Herbalife Ltd

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Bristol-Myers Squibb Company

Buy Bristol-Myers, Says Citi; Stock Jumps 7%

Bristol-Myers Squibb (BMY) stock is up more than 7% today, and leading the Standard & Poor’s 500 index, thanks in part to a Citi Research note which upgraded the company to Buy and raised the stock’s price target to $55 from $33. As analyst Andrew Baum ... [Published BARRONS.com Stocks To Watch Today - May 22 2013]

Entities: Bristol-Myers Squibb Company, Andrew Baum, Standard & Poor's

First reported May 22 2013 - Updated May 22 2013 - 3 reports

Ben Bernanke

Swiss Stocks Rise, Extending Five-Year High as Bernanke Speaks

May 22 (Bloomberg) -- Swiss stocks climbed, extending a five-year high, as Federal Reserve Chairman Ben S. Bernanke signaled that the central bank will continue its loose monetary policy to prevent the U.S. recovery from stalling.Roche Holding AG advanced ... [Published La Repubblica - May 22 2013]

Entities: Ben Bernanke, Roche Holding AG, Schmolz & Bickenbach AG, Givaudan SA

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Merck & Co Inc

Merck & Co sales slide, $15 billion share buyback unveiled

Merck & Co has suffered a decline in sales and profits in the first quarter, hit by patent expiries on its asthma/allergic rhinitis blockbuster Singulair and disappointing sales for some big-earners, notably the diabetes drug Januvia.Net income came in ... [Published Pharma Times - May 02 2013]

Entities: Merck & Co Inc, Stock Buyback, Ezetimibe, Drugs, sitagliptin

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Pfizer Inc

Pfizer's CEO Discusses Q1 2013 Results - Earnings Call Transcript

Pfizer Inc. ( PFE ) Q1 2013 Earnings Call April 30, 2013 10:00 am ET Executives Charles E. Triano – Senior Vice President of Investor Relations Ian Read – Chairman and Chief Executive Officer Frank D’Amelio – Executive Vice President, Business ... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 30 2013]

Entities: Pfizer Inc, Steve Scala, Frank Amelio

First reported Apr 24 2013 - Updated Apr 25 2013 - 1 reports

GlaxoSmithKline plc

GlaxoSmithKline puts 'for sale' sign on drink brands Lucozade and Ribena

By Comments (0) Share GlaxoSmithKline is to press ahead with the sale of Lucozade and Ribena as it tidies up its business, folding more than 50 brands into a new division.The pharmaceuticals giant began a strategic review into the two drinks in February ... [Published Mail Online UK - Apr 24 2013]

Entities: Ribena, Lucozade, GlaxoSmithKline plc

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Novartis names new finance chief to boost productivity

ZURICH: Novartis has named Harry Kirsch as its new CFO, betting that his experience of improving performance at the Swiss drugmaker’s pharmaceuticals division will help it navigate a wave of patent expiries.The surprise announcement is the second leadership ... [Published The Gulf Today - Apr 25 2013]

Entities: Novartis AG, Harry Kirsch, Afinitor, Patent, Daniel Vasella

First reported Apr 21 2013 - Updated Apr 21 2013 - 1 reports

Ex-Stockbroker Accused Of Orchestrating Series Of Multi-Mill. . .

Ex-Stockbroker Accused Of Orchestrating Series Of Multi-Million Dollar Market Manipulation SchemesTargeted News ServiceSANTA ANA, Calif., April 15 -- The U.S. Department of Homeland Security's U.S. Immigration and Customs Enforcement issued the following ... [Published Equities.com - Apr 21 2013]

Entities: Andrew Baum, Rudy Nutrition, HSI, Indictment

First reported Apr 18 2013 - Updated Apr 18 2013 - 1 reports

Ex-stockbroker accused of orchestrating series of multi-million dollar market manipulation schemes

SANTA ANA, Calif. — A former Beverly Hills stock broker made his initial federal court appearance Monday following his indictment on charges alleging he ran several stock manipulation schemes that generated millions of dollars in profits, including one ... [Published U.S. Immigration and Customs Enforcement - Apr 18 2013]

Entities: Andrew Baum, Rudy Nutrition, Market Manipulation, HSI, Indictment

First reported Apr 18 2013 - Updated Apr 18 2013 - 2 reports

GlaxoSmithKline shares soar after FDA approves lung drug

Shares in pharmaceutical giant GlaxoSmithKline rose to the highest price in 11 years after advisers to the US Food and Drug Administration recommended that experimental treatment Breo Ellipta be approved to treat a lung disorder.The shares were up 3.1 ... [Published Irish Times - Apr 18 2013]

Entities: GlaxoSmithKline plc, Ellipta, BREO (Drug)

First reported Apr 17 2013 - Updated Apr 17 2013 - 1 reports

Ex-Stockbroker Arraigned on Charges of Orchestrating Series . . .

Ex-Stockbroker Arraigned on Charges of Orchestrating Series of Multi-Million Dollar Market Manipulation Stock SchemesTargeted News ServiceSANTA ANA, Calif., April 15 -- The U.S. Attorney for Central District of California issued the following news re ... [Published Equities.com - Apr 17 2013]

Entities: Andrew Baum, HSI, Indictment, Stock Market Manipulation

Quotes

"we believe this market will generate sales of up to $35-billion (a year) over the next 10 years and be used in some way in the management of up to 60% of all cancers" Citi analyst Andrew Baum said on Wednesday...

Cancer drugs to rake in R340bn [Published iafrica.com - May 23 2013]

...Analysts are concerned, however, and Andrew Baum at Citibank issued a research note saying that "the weakness of merck's quarter can only be regarded as a clarion call for management and investors"

Merck & Co sales slide, $15 billion share buyback unveiled [Published Pharma Times - May 02 2013]

Analyst Andrew Baum at Citigroup said: "we expect additional divestments over the coming months as gsk's pipeline comes into focus."

GlaxoSmithKline puts 'for sale' sign on drink brands Lucozade and Ribena [Published Mail Online UK - Apr 24 2013]

More Content

sort by: Date \| Relevance
Deals Of The Week Ponders When $2.1 Billion Is ... [Published The IN VIVO Blog - 22 hours ago]
Cancer drugs to rake in R340bn [Published iafrica.com - May 23 2013]
New cancer drugs to be a $ 35 billion market [Published IBNLive India News - May 23 2013]
UPDATE 4: Wednesday's movers: Saks rallies for ... [Published TD Ameritrade - May 22 2013]
Buy Bristol-Myers, Says Citi; Stock Jumps 7% [Published BARRONS.com Stocks To Watch Today - May 22 2013]
UPDATE 3: Wednesday's movers: Drug makers lead ... [Published TD Ameritrade - May 22 2013]
Swiss Stocks Rise, Extending Five-Year High as ... [Published La Repubblica - May 22 2013]
Immunotherapy: The biggest drug class in history? [Published MedCity News - May 22 2013]
Analysts tap the next big thing in biopharma R [Published FierceBiotech - May 22 2013]
New cancer drugs to be a $35 billion market [Published Reuters UK - May 22 2013]
Ahead of the Bell: Analyst upgrades Bristol-Myers [Published CNBC - May 22 2013]
Swiss Stocks Extend Five-Year High Before Berna... [Published La Repubblica - May 22 2013]
Cancer immunotherapy drugs will soon be a $35 b... [Published Firstpost.com - May 22 2013]
Cancer immunotherapy 'next big thing' [Published Trade Arabia - May 22 2013]
Swiss Stocks Little Changed Near Five-Year High... [Published La Repubblica - May 22 2013]
Immune system cancer drugs tipped to be a $35 b... [Published 1440 WNFL - May 22 2013]
Immune system cancer drugs tipped to be a $35 b... [Published CNBC - May 22 2013]
ArborGen Continues Support of “Plant a Tree at ... [Published ADVFN Australia - May 21 2013]
Diverging paths, difficult choices. Winter 2012 [Published Drug Discovery World - May 15 2013]
Merck & Co sales slide, $15 billion share buyba... [Published Pharma Times - May 02 2013]
Merck's CEO Discusses Q1 2013 Results - Earning... [Published Healthcare Sector and Stocks Analysis from Seek ... - May 01 2013]
Pfizer's CEO Discusses Q1 2013 Results - Earnin... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 30 2013]
GE Trees May Be Even More Damaging to the Envir... [Published Mercola - Apr 27 2013]
Novartis names new finance chief to boost ... [Published The Gulf Today - Apr 25 2013]
GlaxoSmithKline puts 'for sale' sign on drink b... [Published Mail Online UK - Apr 24 2013]
Novartis' CEO Discusses Q1 2013 Results - Earni... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 24 2013]
GlaxoSmithKline's CEO Discusses Q1 2013 Results... [Published Healthcare Sector and Stocks Analysis from Seek ... - Apr 24 2013]
Ex-Stockbroker Accused Of Orchestrating Series ... [Published Equities.com - Apr 21 2013]
Ex-stockbroker accused of orchestrating series ... [Published U.S. Immigration and Customs Enforcement - Apr 18 2013]
GlaxoSmithKline shares soar after FDA approves ... [Published Irish Times - Apr 18 2013]